公开(公告)号：CA2447696A1

公开(公告)日：2002-12-05

申请号：CA2447696

申请日：2002-05-28

Applicant: BIO RAD LABORATORIES

Inventor： SAFARIAN ZARA ,  GOODRICH JODI L ,  BINDER STEVEN R

IPC: G01N33/53 ,  G01N33/96 ,  G01N33/48 ,  G01N33/487 ,  G01N33/543

Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.

公开(公告)号：AT163763T

公开(公告)日：1998-03-15

申请号：AT94914954

申请日：1994-05-04

Applicant: BIO RAD LABORATORIES

Inventor： BINDER STEVEN R ,  KING DAVID L

IPC: G01N30/02 ,  G01N30/06 ,  G01N30/08 ,  G01N30/14 ,  G01N30/34 ,  G01N30/46 ,  G01N30/74 ,  G01N30/86 ,  G01N30/88 ,  G01N33/94

Abstract: Biological samples are analyzed for benzodiazepines in a single isocratic analysis using a chromatographic column system containing an immobilized enzyme reactor which cleaves glucuronic acid-conjugated benzodiazepines, an anion exchange column, a hydrophobic cation exchange column and a reverse-phase analytical column. Preferred methods of performing the analysis further involve the use of a hydrophobic cation exchange precolumn prior to the anion exchange column. The system readily lends itself to automation, automatic periodic sampling and benzodiazepine identification and quantification. The system is particularly well adapted to the determination and identification of benzodiazepines in urine samples.

公开(公告)号：WO2005103300A9

公开(公告)日：2006-05-11

申请号：PCT/US2005013637

申请日：2005-04-20

Applicant: BIO RAD LABORATORIES ,  BINDER STEVEN R ,  GLOSSENGER JOHN

Inventor： BINDER STEVEN R ,  GLOSSENGER JOHN

IPC: C12Q1/68 ,  G01N33/48 ,  G01N33/50 ,  G01N33/564 ,  G06F19/00 ,  G06F19/18 ,  G06F19/24

CPC classification number: G01N33/564 ,  G01N2800/24 ,  G06F19/18 ,  G06F19/24 ,  G06K9/6276 ,  G16H50/20

Abstract: An array of autoantibodies is quantitated in a patient sample and analyzed toward a diagnosis of systemic autoimmune diseases. The analysis uses any of various known pattern recognition techniques, for example k-nearest neighbor analysis, to compare the array of quantitation data to sets of data previously obtained from subjects having known systemic autoimmune diseases, thereby determining the particular disease(s) that the patient is suffering from as well as the degree of confidence or likelihood of accuracy of the determination. The method is effective in identifying a single disease and also in identifying two or more diseases simultaneously present. The method is readily susceptible to automated data processing, eliminating much of the human judgment and error that were previously entailed in diagnosing these diseases.

Abstract translation: 对患者样品中的一系列自身抗体进行定量分析，并对系统性自身免疫性疾病的诊断进行分析。 该分析使用各种已知的模式识别技术中的任一种，例如k-最近邻分析，将定量数据阵列与之前从具有已知系统性自身免疫疾病的受试者获得的数据组进行比较，从而确定特定疾病， 患者正在遭受以及确定的准确性的置信度或可能性。 该方法在鉴定单一疾病方面以及鉴定同时存在的两种或多种疾病方面是有效的。 该方法容易受到自动数据处理的影响，消除了以前诊断这些疾病所需的大部分人类判断和错误。

公开(公告)号：WO03087342B1

公开(公告)日：2004-08-05

申请号：PCT/US0309919

申请日：2003-03-28

Applicant: BIO RAD LABORATORIES

Inventor： WATKINS MICHAEL I ,  BINDER STEVEN R ,  RASKIN ALEKSANDER

IPC: G01N33/543 ,  G01N33/53

CPC classification number: G01N33/54393 ,  Y10S435/962

Abstract: Water-soluble polymer is added to the liquid phase in a heterogeneous immunoassay of serum, the polymer having monomers in common with monomers of the solid phase surface. This reduces non-specific binding of IgG's from the serum to the solid phase surface and thereby reduces the occurrence of false positive readings in the immunoassay.

Abstract translation: 在血清的非均相免疫测定中将水溶性聚合物加入到液相中，所述聚合物具有与固相表面的单体相同的单体。 这减少了IgG从血清到固相表面的非特异性结合，从而减少了免疫测定中假阳性读数的发生。

公开(公告)号：WO02096950A9

公开(公告)日：2003-10-09

申请号：PCT/US0217200

申请日：2002-05-28

Applicant: BIO RAD LABORATORIES

Inventor： BINDER STEVEN R ,  GOODRICH JODI L ,  SAFARIAN ZARA

IPC: G01N33/53 ,  G01N33/96 ,  C07K16/36 ,  C07K16/00

CPC classification number: G01N33/96 ,  G01N2333/9108 ,  Y10S435/973

Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.

Abstract translation: 使用血清样品对人因子XIII蛋白的两个亚基中任一个的存在和量的分析作为消除在血清和血浆测试中出现的重大误差源的手段。 对于血清样品，分析亚单位a的存在的阴性结果是验证样品确实为血清的方法，而亚单位a的阴性或阳性结果用于区分血清（阴性）和血浆（阳性）。 亚单位b的存在的阳性结果是验证样品是血清或血浆而不是任何其他生物流体的手段。 亚基b的定量分析是验证样品是否具有预期体积的手段，而不是由于不正确的取样而体积减小。 亚基b的定量分析也是验证血清或血浆样品稀释度的一种手段。

公开(公告)号：AU2013249767A1

公开(公告)日：2014-10-16

申请号：AU2013249767

申请日：2013-03-21

Applicant: BIO RAD LABORATORIES

Inventor： BINDER STEVEN R ,  WALKER ROGER P ,  DELANOY MICHELLE L

IPC: G01N33/53

Abstract: Rheumatoid arthritis and other autoimmune diseases are diagnosed by multiplex assays for antibodies to a panel of antigens that includes cyclic citrullinated peptide and at least five members of a list that includes BRAF1 506-525, BRAF2 656-675, Vimentin (protein) citrullinated, Vimentin 415-433 cit cyclic, Vimentin 58-77 cit3 cyclic, Clusterin 231-250 cit sm1 cyclic, Fibrinogen A 556-575 cit sm cyclic, Fibrinogen A 616-635 cit sm cyclic, Histones2A H2A/a 1-20 cit sm2 cyclic, Filaggrin 48-65 cit2v1 cyclic, BRAF (catalytic domain from v raf murine sarcoma viral oncogene homologue B1, amino acids

公开(公告)号：DE06006417T1

公开(公告)日：2007-01-18

申请号：DE06006417

申请日：2002-05-28

Applicant: BIO RAD LABORATORIES

Inventor： BINDER STEVEN R ,  GOODRICH JODI L ,  SAFARIAN ZARA

IPC: C07K16/36 ,  G01N33/53 ,  C07K16/00 ,  G01N33/96

Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.

公开(公告)号：CA2424764A1

公开(公告)日：2002-04-25

申请号：CA2424764

申请日：2001-09-19

Applicant: BIO RAD LABORATORIES

Inventor： GLOSSENGER JOHN ,  BINDER STEVEN R

IPC: G01N33/564

Abstract: An array of autoantibodies is quantitated in a patient sample and analyzed toward a diagnosis of systemic autoimmune diseases. The analysis uses any of various known pattern recognition techniques to compare the array of quantitation data to sets of data previously obtained from subjects having known systemic autoimmune diseases, thereby determining the particular disease(s) that the patient is suffering from as well as the degree of confidence or likelihood of accuracy of the determination. The method is effective in identifying a single disease and also in identifying two or mor e diseases simultaneously present. The method is readily susceptible to automated data processing, eliminating much of the human judgment and error that were previously entailed in diagnosing these diseases.

公开(公告)号：AU8571998A

公开(公告)日：1999-02-10

申请号：AU8571998

申请日：1998-07-21

Applicant: BIO RAD LABORATORIES

Inventor： BINDER STEVEN R ,  SCOLARI CAROLINE ,  LIKUSKI ROBERT K

IPC: G01N27/447 ,  G01N27/26

Abstract: Identification and quantification of paraproteins in a sample is achieved by Fourier analysis of mobility-based electropherograms obtained from capillary electrophoresis. The use of a computer algorithm to analyze capillary electrophoresis data, provides the clinician with methods of detecting levels of paraproteins in serum as low as 0.05 g/dL. Additionally, an individual paraprotein can be located on an electropherogram and used to monitor its increased or decreased production in an individual.

公开(公告)号：HK67994A

公开(公告)日：1994-07-22

申请号：HK67994

申请日：1994-07-14

Applicant: BIO RAD LABORATORIES

Inventor： BINDER STEVEN R

IPC: G01N30/14 ,  G01N30/46 ,  G01N30/88 ,  G01N33/94 ,  G01N33/48 ,  G01N30/02